QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:ESPR

Esperion Therapeutics Stock Forecast, Price & News

$29.22
+0.18 (+0.62 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.33
Now: $29.22
$30.49
50-Day Range
$25.12
MA: $29.72
$36.89
52-Week Range
$23.90
Now: $29.22
$53.73
Volume640,137 shs
Average Volume936,262 shs
Market Capitalization$816.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics logo

Headlines

Is Esperion Therapeutics (ESPR) a Smart Long-term Buy?
February 26, 2021 |  finance.yahoo.com
Recap: Esperion Therapeutics Q4 Earnings
February 23, 2021 |  finance.yahoo.com
Is Esperion Therapeutics (ESPR) Stock a Buy For 2021?
February 3, 2021 |  finance.yahoo.com
Esperion Therapeutics: The Good, Bad and Ugly
February 3, 2021 |  finance.yahoo.com
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down
January 14, 2021 |  finance.yahoo.com
Notable Wednesday Option Activity: ESPR, CFR, DD
January 13, 2021 |  nasdaq.com
Why Esperion Therapeutics Stock Is Falling Today
January 13, 2021 |  finance.yahoo.com
Is ESPR A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
Why BioLine, Esperion And More Are Moving Today
December 16, 2020 |  benzinga.com
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
December 15, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903
Employees193
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$148.36 million
Book Value$0.73 per share

Profitability

Net Income$-97,170,000.00

Miscellaneous

Market Cap$816.49 million
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

886th out of 1,971 stocks

Pharmaceutical Preparations Industry

424th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$29.22
+0.18 (+0.62 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

Is Esperion Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Esperion Therapeutics?

Wall Street analysts have given Esperion Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Esperion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Esperion Therapeutics
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) issued its quarterly earnings results on Monday, February, 22nd. The biopharmaceutical company reported ($3.89) EPS for the quarter, missing the consensus estimate of ($3.76) by $0.13. The biopharmaceutical company earned $9.64 million during the quarter, compared to the consensus estimate of $12.52 million. Esperion Therapeutics had a negative net margin of 46.15% and a negative trailing twelve-month return on equity of 629.88%. The company's revenue was up 881.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.26) earnings per share.
View Esperion Therapeutics' earnings history
.

How has Esperion Therapeutics' stock been impacted by Coronavirus?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ESPR shares have decreased by 31.9% and is now trading at $29.22.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ESPR?

9 Wall Street analysts have issued twelve-month price objectives for Esperion Therapeutics' shares. Their forecasts range from $24.00 to $134.00. On average, they anticipate Esperion Therapeutics' share price to reach $52.89 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 60, Pay $1.08M)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 39, Pay $485.5k)
  • Mr. Sheldon L. Koenig, Chief Operating Officer (Age 55)
  • Dr. Kenneth J. Fiorelli, Chief Technical Operations Officer
  • Mr. Benjamin Church, Head of Corp. Communications & Investor Relations
  • Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 48)
  • Renee Marotta, Head of Marketing
  • Ms. Ashley Hall, Chief Devel. Officer (Age 49)
  • Ms. April Seiler, Sr. Director of Project Management
  • Roberta Peterson, Sr. Director of National Accounts

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include (ALDW) (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), The Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.40%), Rhenman & Partners Asset Management AB (2.12%), Amundi Pioneer Asset Management Inc. (1.36%), Bamco Inc. NY (1.34%), Northern Trust Corp (1.17%) and Hood River Capital Management LLC (1.11%). Company insiders that own Esperion Therapeutics stock include Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics
.

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Bailard Inc., Russell Investments Group Ltd., Bank of New York Mellon Corp, DCF Advisers LLC, Northern Trust Corp, SG Americas Securities LLC, and Nuveen Asset Management LLC.
View insider buying and selling activity for Esperion Therapeutics
or view top insider-selling stocks.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Morgan Stanley, Rhenman & Partners Asset Management AB, Endurant Capital Management LP, Voloridge Investment Management LLC, Hood River Capital Management LLC, Barclays PLC, and Bamco Inc. NY. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $29.22.

How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of $816.49 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

Esperion Therapeutics employs 193 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

Where are Esperion Therapeutics' headquarters?

Esperion Therapeutics is headquartered at 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.